A record of what Goldman Sachs Analysis said publicly, with the source. Not advice.
“Bullish on Piramal Pharmaceuticals with a target price of ₹250 per share. Despite transitory near-term pressure in CDMO in FY26 due to destocking, the company is well-placed for top-quartile profit growth driven by high operating/financial leverage as the CDMO business recovers post-FY26, CHG capacity ramps up from 2HFY26, and the ICH business turns around.”
Goldman Sachs Analysis’s track record (trackable calls only): 63 graded calls · 95% CI 39–63%
Piramal Pharma LtdBullishCalled 12 Nov 2025Graded 12 Nov 2026
R4 TARGET_CALL: entered ₹193.84 on 2025-11-13 (next trading session's close); neither target nor stop reached by window end 2026-11-12. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.
How it played out
How this is worked out- Time to target
- The target was not reached on a close inside the window.
- Worst close against it
- The closing price went as far as 31.25% against the call up to 12 Nov 2026, when the call was decided, measured from the entry price. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.